Mammoth Biosciences
PrivateLast Round
Series D
Sep 9, 2021
Est. Valuation
$1B
Total Funding Raised
$287.6M
Company Overview
Mammoth Biosciences is a biotechnology company that develops long-term curative therapies and decentralized precision diagnostics using proprietary ultracompact CRISPR proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical Devices
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mammoth Biosciences Comparables
Compare Mammoth Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Metagenomi | 85% | |
| Arbor Biotechnologies | 82% | |
| Scribe Therapeutics | 77% |
Mammoth Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 9, 2021 | ||||
| Series C | Nov 1, 2020 | ||||
| Grant | Jul 30, 2020 | ||||
| Series B | Jan 30, 2020 | ||||
| Series A | Jul 31, 2018 | ||||
Seed | Nov 1, 2017 |
Key People
Founding team and executive leadership
Mammoth Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series D |
| NFX | Series A, Series B, Series D, Seed, Pre Seed |
| Pacific 8 Ventures | Series B |
| NIH RADx | Grant |
| Plum Alley Investments | Series B |
| StepStone Group | Series D |
| Sixth Street Partners | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Preclinical data for MB-111 to be presented at industry congress.
- Oct 1, 2025
Presenting at the European Society of Gene & Cell Therapy Congress.
Recent news
Latest coverage and updates
- is_developingJun 25, 2026
Mammoth Biosciences, Inc. is developing gene-editing therapies for rare and inherited diseases on Jun 25th '26.
- partners_withJun 25, 2026
Mammoth Biosciences, Inc. partnered with M42 Ltd. on Jun 25th '26.
- attends_eventJun 25, 2026
Mammoth Biosciences, Inc. attended event BIO International Convention 2026 on Jun 25th '26.
Mammoth Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Mammoth Biosciences's valuation, stock price, and market status.
Is Mammoth a public or private company?
Mammoth is a private company.
What is the current stock price of Mammoth?
Mammoth is a private company with no public stock price. No recent secondary market data is available.
How much is Mammoth worth (valuation)?
Mammoth's valuation is estimated at $1.0B based on funding round data.
Can I buy Mammoth stock?
Mammoth shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Mammoth's last funding round?
Mammoth's most recent funding round was Series D on September 9, 2021.
Who are the main investors in Mammoth?
Key investors in Mammoth include Redmile Group, NFX, Foresite Capital, Decheng Capital, Mayfield Fund.
Will Mammoth IPO soon?
No public IPO plans have been announced for Mammoth.
How can I track Mammoth secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mammoth's secondary market activity and sign up for updates.